Effects of long-term intake of retinol on selected clinical an laboratory indexes

American Journal of Clinical Nutrition

Volumn 69, Issue 5, 1999, Pages 937-943

  Cartmel, Brenda ^a,b   Moon, Thomas E ^a   Levine, Norman ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

Actinic keratoses; Adults; Arizona; Humans; Long term effects; Prevention; Retinol; Skin cancer

Indexed keywords

ALKALINE PHOSPHATASE; CHOLESTEROL; RETINOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CHEMISTRY; BLOOD EXAMINATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SKIN CANCER; SYMPTOMATOLOGY; VITAMIN INTAKE;

EID: 0032935611     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/69.5.937     Document Type: Article

References (29)

1. Lippman AM, Heyman RA, Kurie JM, et al. Retinoids and chemoprevention: clinical and basic studies. J Cell Biochem 1995;22(suppl):1-10.
2. Mayne ST, Lippman SM. Cancer prevention: chemoprevention agents. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer. Principles and practice of oncology. 5th ed. Philidelphia: Lippincott-Raven, 1997.
3. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801.
4. Pastorino U, Infante M, Mailoi M, et al. Adjuvant treatment of stage 1 lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:1216-22.
5. Tangrea JA, Edwards BK, Taylor PR, et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J Natl Cancer Inst 1992;84:328-32.
6. Peck GL, DiGiovanna JJ, Sarnoff DS, et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J Am Acad Dermatol 1988;19:176-85.
7. Tangrea JA, Kilcoyne RF, Taylor PR, et al. Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin. Arch Dermatol 1992;128:921-5.
8. Bendich A, Langseth L. Safety of vitamin A. Am J Clin Nutr 1989;49:358-71.
9. Goodman GE, Omenn GS, Thornquist MD, et al. The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high-risk populations: pilot study with cigarette smokers. Cancer Epidemiol Biomarkers Prev 1993;2:389-96.
10. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
11. Omenn GS, Goodman GE, Thornquist M, et al. Long term vitamin A does not produce clinically significant hypertriglyceridemia: results from CARET, the Beta-Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 1994;3:711-3.
12. Stauber PM, Sherry B, VanderJagt DJ, Bhagavan HN, Garry PJ. A longitudinal study of the relationship between vitamin A supplementation and plasma retinol, retinyl esters, and liver enzyme activities in a health elderly population. Am J Clin Nutr 1991;54:878-83.
13. Herbert V. Toxicity of 25,000 IU vitamin A supplements in "health" food users. Am J Clin Nutr 1982;36:185-6 (letter).
14. Geubel AP, De Galocsy C, Alves N, et al. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology 1991;100:1701-9.
15. Lieber CS. Interaction of alcohol with other drugs and nutrients. Drugs 1990;40(suppl):23-44.
16. Miller RK, Hendrickx AG, Mills JL, et al. Periconceptional vitamin A use: how much is teratogenic? Reprod Toxicol 1998;12:75-88.
17. Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995;333:1369-73.
18. Moon TE, Levine N, Cartmel B, et al. Design and recruitment for retinoid skin cancer prevention (SKICAP) trials. Cancer Epidemiol Biomarkers Prev 1995;4:661-9.
19. Moon T, Levine N, Cartmel B, et al. Use of retinol to prevent squamous cell skin cancer in moderate-risk subjects. Cancer Epidemiol Biomarkers Prev 1997;6:949-56.
20. Pastorino U, Chiesa G, Infante M, et al. Safety of high-dose vitamin A. Randomized trial on lung cancer chemoprevention. Oncology 1991;48:131-7.
21. Chuang-Stein C. Laboratory data in clinical trials: a statistician's perspective. Control Clin Trials 1998;19:167-77.
22. Omenn GS, Goodman G, Thornquist M, et al. The Carotene and Retinol Efficacy Trial (CARET) to prevent lung cancer in high risk populations: pilot study with asbestos-exposed workers. Cancer Epidemiol Biomarkers Prev 1993;2:381-7.
23. Teelmann K. Retinoids: toxicology and teratogenicity to date. Pharmacol Ther 1989;40:29-43.
24. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
25. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. JAMA 1993;269:3002-8.
26. Marsden J. Hyperlipidaemia due to isotretinoin and etretinate: possible mechanisms and consequences. Br J Dermatol 1986;114:401-7.
27. Bershad S, Rubinstein A, Paterniti JR, et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313:981-5.
28. Vahlquist C, Michaelsson G, Vahlquist A, et al. A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Br J Dermatol 1985;112:69-76.
29. Davis CE, Rifkind BM, Brenner H, et al. A single cholesterol measurement underestimates the risk of coronary heart disease: an empirical example from the Lipid Research Clinics Mortality Follow-up Study. JAMA 1990;264:3044-6.